Drug Trial Radar · NCT07826689
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- Progentos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body. Some subjects will have lumbar punctures performed to measure the amount of drug that crosses the blood-brain barrier since that is the site of drug activity. Phase 2a will be a 6-month trial to test the ability of once monthly dosing of PRO-1562 to promote remyelination of the CNS and provide clinical benefit to adult patients with relapsing multiple sclerosis (RMS) who also have long-term vision problems diagnosed as chronic optic neuropathy. The benefits of remyelination will be measured using tests of visual acuity, speed of optic nerve conduction signals, and clinical assessments of cognitive and motor function. PRO-1562 will be added on to a stable regimen of MS disease modifying therapy.
Conditions
- Multiple Sclerosis
Interventions
PRO-1562 Oral CapsulesDrug
Oral, CNS-penetrant small molecule designed to induce remyelination
Placebo Oral CapsuleDrug
Placebo filled capsules that look like the active intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Incidence of ≥Grade 2 treatment-emergent adverse eventsTime frame: From enrollment until 7 days post dose
- Phase 2 Change from baseline P100 VEP latencyTime frame: From enrollment until the end of 6 months of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.